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Background: Nuclear factor (erythroid-derived 2)-like (Nrf)2 and metallothionein have been implicated in
carcinogenesis. This study investigated the expression of Nrf2 and of Nrf2-targeted genes (NQO1 and GCLC) and the
genes for the metallothionein (MT) isoforms (MT-1A and MT-2A) in human lung cancer and cancer-surrounding
tissues.
Methods: Surgically removed lung cancer samples (n = 80) and cancer-surrounding tissues (n = 38) were collected
from Zunyi Medical College Hospital, China. Total RNA was extracted, purified, and used for real-time reverse
transcription-PCR analysis of interested genes.
Results: Expression of the Nrf2-targed genes NQO1 and GCLC tended to be higher (30 to 60%) in lung cancers, but
was not significantly different from that in peri-cancer tissues. By contrast, expression of the genes for M)-1A, MT-2A,
and the metal transcription factor MTF-1 were three-fold to four-fold lower in lung cancers.
Conclusion: In surgical samples of lung cancer, MT expression was generally downregulated, whereas Nrf2 expression
tended to be upregulated. These changes could play an integral role in lung carcinogenesis.
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Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is a tran-
scription factor belonging to the ‘cap “n” collar’ subfamily
of the basic-leucine zipper (bZIP) family of transcription
factors, which plays a significant role in adaptive responses
to oxidative stress [1]. Activation of Nrf2 can have good,
bad, and ugly effects in biology, especially during carcino-
genesis [1,2]. However, little is known about the role of
NRF2 expression in surgically removed lung cancers.
Metallothioneins (MTs) are a group of low-molecular
weight, cycteine-rich, metal-binding proteins, which are
encoded by a family of genes located at 16q13. This fam-
ily of proteins consists of 10 functional isoforms in
humans, with MT-1A and MT-2A being the predomin-
ant forms [3]. It has been shown that aberrant expres-
sion of MTs is related to tumor type and different stages
of tumor development and progression [3,4].* Correspondence: guiyou515@163.com
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duced MT gene expression are frequently seen in hepa-
tocellular carcinoma (HCC) [5-7]. Both increased [8]
and suppressed [9] MT expression have been reported
in lung cancer compared with normal lungs. However,
little is known about the expression of MT in lung tu-
mors and peri-tumor tissues.
MT is silenced via methylation status changes [5].
Methylation of MT-1A and MT-2A in malignant meso-
thelioma was shown to be associated with tumor grade
histology and lymph-node involvement [10]. MT protein
stained positively in lung adenocarcinoma, but was ab-
sent in small cell lung carcinoma [11], suggesting that
MT expression in the lung is tumor type-specific.
To further explore the role of Nrf2 and MT expression
in lung carcinogenesis, this study used surgically removed
lung cancer samples and available cancer-surrounding tis-
sues to examine expression of these antioxidant compo-
nents. Downregulation of MT-1A and MT-2A was found
in the surgical stage of lung cancers, whereas the NRF2-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Primer sequences for real-time RT-PCR
Gene GenBank nyu Forward Reverse
GADPH NM_002046 ACAGTCAGCCGCATCTTCTT ACGACCAAATCCGTTGACTC
GCLC NM_001498 GTGGATGTGGACACCAGATG GCGATAAACTCCCTCATCCA
MT-1A NM_005946 GCAAATGCAAAGAGTGCAAA CAGCTGCACTTCTCTGATGC
MT-1E NM_175617 GGGCTTTCTTTGCCCTCATT CTGTCCTGCCCCATCTGAAT
MT-1G NM_005950 CCTGTGCCGCTGGTGTCT TGCAGCCTTGGGCACACT
MT-2A NM_005953 GTGTGCCCAAGGCTGCAT TTGTGGAAGTCGCGTTCTTTAC
MT3 NM_005954 AGTGCGAGGGATGCAAATG GCCTTTGCACACACAGTCCTT
MT-4 U07807 TCCAGGCCTCATGTGATTCAC CCCTCTTGGCTAGGCACAGT
MTF-1 NM_005955 GCGAGTGCACACGAAGGA CTGATGTGCTTTCAGCCTGTACA
NQO1 NM_000903 GTTGCCTGAAAAATGGGAGA AAAAACCACCAGTGCCAGTC
NRF2 NM_006164 CGGTATGCAACAGGACATTG GTTTGGCTTCTGGACTTGGA
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Lung cancer samples were obtained from specimens
removed surgically during the period March 2008 to
May 2009 at Zunyi Medical College Hospital (Guizhou,
China). In total, 80 lung cancer specimens, both benign
and malignant tumors, were collected, together with 38
available cancer-surrounding tissues.
Ethics
All the human studies were approved by the Institu-































Figure 1 Expression of the nuclear factor (erythroid-derived)-like (Nrf
(n = 62) and cancer-surrounding tissues (n = 21).College Hospital. All patients were informed and signed a
consent to allow to use the surgical specimens for scientific
research.
RNA isolation
Total RNA was extracted (Trizol reagent; Huashun Bio-
engineering Co, Shanghai, China) in accordance with the
manufacturer’s instructions. RNA quality and quantity
was determined spectrometrically, with a 260/280 nm
ratio of greater than 1.8.
Real-time reverse transcription-PCR analysis of Nrf2 and MT
Total RNA was then used for real-time reverse-
transcription (RT)-PCR and specific cDNAs were ampli-
fied (SYBR® PrimeScriptTM RT-PCR Kit; TaKaRa,
Dalian, China). The Nrf2 and MT isoform primers wereGCLC
Cancer
Peri-cancer


































Figure 2 Expression of metallothionein (MT)-1A, MT-2A, and metal transscription factor (MTF)1 in human lung cancers (n = 80) and
cancer-surrounding tissues (n = 38). *Significantly different from lung cancers, P < 0.05.
Table 2 Expression of MT isoforms in lung cancers and
cancer-surrounding tissuesa,b
Lung cancer tissue Peri-cancer tissue
MT-1A 11.59 ± 1.16c 47.03 ± 0.26
MT-1E 0.52 ± 0.23c 4.16 ± 0.96
MT-1G 0.66 ± 0.18c 1.71 ± 0.55
MT-2A 12.68 ± 1.76c 33.88 ± 8.87
MT-3 0.86 ± 0.27 1.52 ± 0.72
MT-4 0.06 ± 0.02 0.18 ± 0.07
MTF1 11.76 ± 3.52c 34.56 ± 12.56
Abbreviations: MT metallothionein; MTF Metal transcription factor.
aTotal RNA was extracted from surgically removed lung cancers (n = 62 to 80)
and cancer-surrounding tissues (n = 21 to 38), and the expression of MT
isoforms was examined via real-time reverse transcription (RT)-PCR.
bData are expressed as a percentage of the expression of the housekeeping
gene glyceraldehyde 3-phosphate dehydrogenase.
cSignificantly different from cancer-surrounding tissues p < 0.05.
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shown in Table 1. Real-time PCR was performed using a
real-time PCR System (IQ5; Bio-Rad Laboratories, Inc.,
Hercules, CA, USA) in a 96-well optical plate format. The
relative differences in expression between groups were
expressed using cycle time (Ct) values. The Ct values of
the interested genes were first normalized to β-actin in the
same sample, and then the relative differences between
the control and treatment groups were calculated and
expressed as relative increases, setting controls as 100%.
Statistical analysis
Data are expressed as mean ± SEM. The SPSS statistical
program (version11.5 for Windows; SPSS Inc., Chicago,
IL, USA) was used for ANOVA, followed by Turkey’s mul-
tiple comparison tests. P < 0.05 was considered significant.
Results
NRF2 and NRF2 target genes
Expression of NRF2 was generally unchanged (34.12 ± 8.52
in lung cancer versus 33.80 ± 5.84 in peri-cancer tissues).
Expression of the NRF2-target genes NQO1 (15.84 ± 4.85
versus 9.67 ± 2.01) and GCLC (7.68 ± 1.41 versus 5.88 ±
0.85) tended to increase, but was not significant because of
very large individual variations (Figure 1).
MT-1A, MT-2A, and MTF1
Expression of MT-1A and MT-2A in lung cancer and sur-
rounding tissues are shown in Figure 2. MT-1A and MT-
2A are the two most abundant MT isoforms in the lung.
Expression of MT-1A mRNA was decreased four-fold in
lung cancers (11.59 ± 1.16 in lung cancer versus 47.03 ±10.26 in peri-cancer tissues. Expression of MT-2A
followed a similar pattern, being approximately three-fold
lower in lung cancers (12.68 ± 1.76 versus 33. 88 ± 8.87).
Expression of MTF-1, a transcription factor for MT bio-
synthesis, was also lower in tumor compared with peri-
cancer tissues (11.76 ± 3.52 versus 34.56 ± 12.56).
Other MT isoforms
Expression of MT-3 and MT-4 was very low (0.35 and
0.41, respectively), and there was no difference in lung
cancer compared with cancer-surrounding tissues
(Table 2). Regarding MT isoforms, MT-1E and MT-1G
were also downregulated in lung cancer tissues (Table 2),
consistent with their methylation status and reduced ex-
pression in malignancies [12-14].
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In the present study, we used surgically removed lung
cancer and cancer-surrounding tissues to examine the
transcript levels of the two major antioxidant pathways,
the Nrf2 pathway and MT molecules. The results clearly
showed downregulation of MT isoforms in surgically re-
moved lung tumors compared with the corresponding
tumor-surrounding tissues. There was no difference in
expression of Nrf2 between tumor and peri-cancer tis-
sues, but the Nrf2 targeted genes NQO1 and GCLC
tended to be higher in lung cancer tissues.
The role of MT in lung cancers is dependent on the type
and stage of tumor development [3]. In animal studies,
MT stained negative in diethylnitrosamine-induced lung
cancers [15,16], and deficiency of MT makes MT-null mice
more susceptible to chemical-induced lung tumors [17].
All these experimental studies suggest that MT plays
an important role in host defense against lung cancer
development, and reduced MT expression is frequently
associated with malignancies, such as HCC [3-5] and
lung cancers [9]. Suppressed MT expression is related to
epigenetic mechanisms such as MT gene methylation.
Indeed, MT gene methylation ia evident in both human
lung cancer [9] and HCC [3-5]. The methylation status
of MT in lung cancer warrants further investigation.
Large discrepancies in MT expression exist between dif-
ferent tumor types, and no distinct and reliable associ-
ation exists between MT-1A and MT-2A expression in
tumor tissues.
The roles of MT expression in tumor prognosis and
therapy resistance are a matter debate. For example, in
one study, MT positivity was obvious in 32 of 43 (74%)
cases of squamous cell lung carcinoma, and in 12 of 35
(34%) cases of adenocarcinoma, whereas it was negative in
all 11 cases of small cell lung carcinoma examined [11].
The different patterns of MT expression may relate to the
antioxidant function of the protein in protecting against
toxic stimuli [4]. A very large individual variation in MT
expression also exists. In the present study, the difference
in MT isoform expression between individuals was over
100-fold, and polymorphism of MT may dispose individ-
uals to lung cancer development and progression. These
possible links warrant further investigation.
Nrf2 is a transcription factor that positively regulates
the basal and inducible expression of a large battery of
cytoprotective genes. These gene products include pro-
teins that catalyze oxidant reduction reactions (NQO1),
glutathione synthesis (GCLC), and conjugation reactions
(glutathione-S-transferase), and the efflux of potentially
toxic xenobiotics and xenobiotic conjugates [18]. Thus,
expression of the Nrf2-dependent proteins is crucial for
ameliorating or eliminating toxicants/carcinogens to
maintain cellular redox homeostasis. In addition, Nrf2
and Nrf2-targeted gene overexpression could also berelated to abnormal expression of Kelch-like ECH-
associated protein 1 [19]. In general, NRF2 is the cellular
mechanism of cell survival. However, the ‘dark’ side of
Nrf2 is that the damaged cells could escape clearance,
allowing them to proliferate to produce cancer [20].
Nrf2 and its downstream genes are overexpressed in
many cancer cell lines and human cancer tissues, giving
cancer cells an advantage for survival and growth [2,20].
Thus, Nrf2-targeted gene overexpression in lung cancers
could be a mechanism of lung carcinogenesis [1,2,20].
Conclusions
In the current study, we found downregulation of MT
isoforms in human lung cancers, especially in malignant
tumors compared compared with cancer-surrounding
tissues. By contrst, the Nrf2 targeted genes NQO1 and
GCLC tended to increase. All these changes could play
an intergral role in lung carcinogenesis.
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